T1	p 61 114	bestatin of acute nonlymphocytic leukemia in adults .
T2	p 375 461	with remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL
T3	p 628 662	101 eligible cases ( bestatin : 48
T4	p 931 949	15-49 yr age group
T5	p 959 971	50-65 yr age
T6	p 1151 1167	elderly patients
T7	i 37 55	chemoimmunotherapy
T8	i 61 69	bestatin
T9	i 121 137	immunomodulating
T10	i 146 154	bestatin
T11	i 163 171	Ubenimex
T12	i 337 359	bestatin immunotherapy
T13	i 363 374	combination
T14	i 380 414	remission maintenance chemotherapy
T15	i 552 566	bestatin group
T16	i 572 577	mg/bw
T17	i 587 591	po )
T18	i 598 599	)
T19	i 608 615	control
T20	i 700 708	bestatin
T21	i 750 757	control
T22	i 879 887	bestatin
T23	i 1008 1016	Bestatin
T24	o 724 740	longer remission
T25	o 803 813	survival .
T26	o 826 851	prolongation of remission
T27	o 1114 1136	survival and remission